SINT.NASDAQSintx Technologies, INC
10-Q: SINTX Technologies Reports Q1 2025 Results, Focuses on Biomedical Applications
Sentiment:
Quarterly Report
SINTX Technologies reports a net loss for Q1 2025, while strategically shifting focus towards biomedical applications and streamlining operations.
Delay expectedThe Companys efforts to fully repair the damaged furnace continue to be delayed.
Capital raiseOn February 20, 2025, the Company entered into a private placement transaction with certain institutional and accredited investors for aggregate gross proceeds of $5.0 million.The Company intends to use the net proceeds from the Private Placement for general corporate purposes and working capital.
Worse than expectedThe company's net loss increased significantly compared to the same period last year.Total revenue decreased substantially due to a decline in grant and contract revenue.
Summary
- SINTX Technologies, Inc. reported its financial results for the first quarter of 2025.
- The company incurred a net loss of $2.3 million, compared to a net loss of $0.9 million for the same period in 2024.
- Total revenue decreased by 46% to $369,000, primarily due to a decrease in grant and contract revenue.
- Product revenue remained relatively unchanged at $291,000.
- Research and development expenses decreased by 45% to $1.1 million.
- The company is strategically focusing on biomedical applications and has sold its TA&T subsidiary.
- SINTX completed a private placement transaction in February 2025, raising $5.0 million in gross proceeds.
- Management believes there is no significant uncertainty of the company's ability to continue as a going concern through at least May 15, 2026.
Sentiment
Score: 4
Explanation: The report indicates a challenging financial situation with increased losses and decreased revenue, but the company is taking steps to improve its financial position through cost reductions, strategic shifts, and capital raising.
Positives
- SINTX Technologies secured $5.0 million in gross proceeds through a private placement in February 2025.
- Research and development expenses decreased by $0.9 million, indicating improved cost management.
- The sale of TA&T is expected to reduce the net loss.
- Cash and cash equivalents increased to $6.5 million as of March 31, 2025.
- Management believes there is no significant uncertainty of the company's ability to continue as a going concern through at least May 15, 2026.
Negatives
- The company experienced a net loss of $2.3 million in Q1 2025, a significant increase from the $0.9 million loss in Q1 2024.
- Total revenue decreased by 46% due to a substantial decline in grant and contract revenue.
- The company has an accumulated deficit of $284 million as of March 31, 2025.
- The company will require substantial future capital in order to continue operating our business.
Risks
- The company's continuation as a going concern is dependent upon its ability to increase sales, decrease expenses and raise additional funding.
- Additional equity financing, if available to the Company, will most likely be dilutive to its current stockholders.
- If the Company is not able to obtain additional debt or equity financing on a timely basis, the impact on the Company will be material and adverse.
Future Outlook
The company is focusing on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications and is actively generating additional scientific and clinical data to have it published in leading industry publications.
Industry Context
The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors | NA | Jay M. Moyes | 2025-04-03 | Appointment |
| Board of Directors | NA | Robert D. Mitchell | 2025-04-03 | Appointment |
| Board of Directors | NA | Mark Anderson | 2025-04-03 | Appointment |
| Board of Directors | NA | Chris Lyons | 2025-04-03 | Appointment |
| Board of Directors | NA | Gregg Honigblum | 2025-04-03 | Appointment |
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new shares in the private placement.
- Employees may have been affected by the Company-wide reduction in the workforce.
- Customers in the biomedical sector may benefit from the company's strategic focus on medical device innovation.
Next Steps
- The company intends to use the net proceeds from the Private Placement for general corporate purposes and working capital.
- Management will work with the insurance company to continue to fund the repair of the furnace.
- When the furnace is fully repaired, management intends to sell the furnace, and related equipment, to a third party.
Key Dates
| Date | Description |
|---|---|
| 1996-12 | SINTX Technologies formed in December 1996 |
| 2008 | Spinal implants made from SINTX silicon nitride have been successfully implanted in humans since 2008 |
| 2021-02-25 | Company entered into an Equity Distribution Agreement with Maxim Group LLC |
| 2024-02-02 | Company closed a public offering of 80,000 units |
| 2024-03-22 | Company suspended sales under the ATM Agreement and terminated the continuous offering. |
| 2024-03-26 | Company closed a public offering of 142,000 shares of the Company's common stock |
| 2024-04-05 | Company closed a public offering of 358,000 shares of the Company's common stock |
| 2024-05-28 | The Company effected a 1 for 200 reverse stock split of the Company's common stock. |
| 2024-07-11 | Company filed a Prospectus Supplement with the SEC adjusting the amount available for sale under the ATM Agreement to $3.1 million |
| 2024-08-08 | The Board of Directors approved a plan to implement a Company-wide reduction in the workforce. |
| 2024-08-12 | The Board of Directors of the Company approved a plan to cease efforts to make the armor plant operational. |
| 2025-02-19 | Company entered into an Entity Acquisition Agreement with Tethon Corporation to sell TA&T |
| 2025-02-20 | Company entered into a private placement transaction with certain institutional and accredited investors for aggregate gross proceeds of $5.0 million |
| 2025-03-19 | Form 10-K for the year ended December 31, 2024, was filed with the SEC |
| 2025-03-27 | The Company filed an S-3 to register the above mentioned shares, effective March 27, 2025. |
| 2025-04-03 | The Board of Directors of the Company appointed Jay M. Moyes, Robert D. Mitchell, Mark Anderson, Chris Lyons and Gregg Honigblum to the Board of Directors of the Company, effective April 3, 2025. |
| 2025-05-02 | The Board of Directors ( the Board) of SINTX Technologies, Inc. (the Company) approved and on May 5, 2025, the Company entered into new Executive Employment Agreements (the Agreements) with its Chief Executive Officer and President Eric K. Olson and its Chief Investment Officer Gregg Honigblum. |
| 2025-05-13 | 2,508,706 shares of common stock, $ 0.01 par value, were outstanding at May 13, 2025. |
| 2025-05-15 | Date of report filing. |
Keywords
SINTX Technologies, biomedical applications, financial results, silicon nitride, private placement, TA&T, revenue, net loss, research and development, operating expenses
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.